These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29780111)

  • 1. Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma.
    Godo S; Yoshida Y; Kawamorita N; Mitsuzuka K; Kawazoe Y; Fujita M; Kudo D; Nomura R; Shimokawa H; Kushimoto S
    Intern Med; 2018 Oct; 57(19):2895-2900. PubMed ID: 29780111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
    Rexer H; Bedke J
    Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
    [No Abstract]   [Full Text] [Related]  

  • 3. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma.
    Yamamoto Y; Otori T; Inoue R; Yano S; Hirata H; Matsumoto H; Matsuyama K; Matsuyama H
    J Clin Pharmacol; 2020 Feb; 60(2):256-263. PubMed ID: 31538342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment Outcome of Axitinib for Metastatic Renal-Cell Carcinoma Patients].
    Kusakabe N; Osawa T; Miyata H; Kikuchi H; Matsumoto R; Maruyama S; Abe T; Shinohara N
    Hinyokika Kiyo; 2018 Sep; 64(9):353-358. PubMed ID: 30369225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
    Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
    Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib for the treatment of metastatic renal cell carcinoma.
    Parekh H; Griswold J; Rini B
    Future Oncol; 2016 Feb; 12(3):303-11. PubMed ID: 26769075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal Pneumatosis: A Manifestation of Rarely Reported Axitinib-Associated Necrotizing Enterocolitis.
    Akhtar K; Zayac A; Lemke S
    Am J Ther; 2018; 25(6):e763-e765. PubMed ID: 29746290
    [No Abstract]   [Full Text] [Related]  

  • 9. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
    Tomita Y; Uemura H; Oya M; Shinohara N; Habuchi T; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Rini BI
    BMC Cancer; 2019 Jan; 19(1):17. PubMed ID: 30616534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature.
    Nigro O; Pastore A; Tartaro T; Bolzacchini E; Tuzi A; Pinotti G
    Anticancer Drugs; 2019 Apr; 30(4):425-427. PubMed ID: 30640790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
    Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
    Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma.
    Nakai Y; Takeuchi A; Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Minami K; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Morizane S; Kawasaki Y; Morooka D; Shimazui T; Yamamoto Y; Nakagomi H; Tomida R; Ito YM; Murai S; Kitamura H; Nishiyama H; Shinohara N;
    J Geriatr Oncol; 2021 Jun; 12(5):834-837. PubMed ID: 33388281
    [No Abstract]   [Full Text] [Related]  

  • 13. Axitinib in the treatment of metastatic renal cell carcinoma.
    Ho TH; Jonasch E
    Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report.
    Murata M; Ikeda Y; Hasegawa G; Nakagawa Y; Nishiyama T
    J Med Case Rep; 2019 Apr; 13(1):98. PubMed ID: 31006385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.
    Umeyama Y; Shibasaki Y; Akaza H
    Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting response with polycythemia to third-line axitinib treatment in metastatic renal cell carcinoma: Very rare case presentation.
    Dulgar O; Cil I; Zirtiloglu A; Tural D
    J Oncol Pharm Pract; 2019 Sep; 25(6):1512-1515. PubMed ID: 30058939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
    Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
    Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
    [No Abstract]   [Full Text] [Related]  

  • 19. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
    Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
    BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
    Miyake H; Harada KI; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.